

#ADHERENCE2016 Ending AIDS as a Public Health Threat: The Power of Change


MAY 9-11, 2016 • FORT LAUDERDALE

Jointly sponsored by





Postgraduate Institute for Medicine



SESSION TITLE

Paradigm Shift(ing): When Treatment is Prevention, What Then Do We Mean by Prevention?

> Presenter Jeremiah Johnson HIV Prevention Research and Policy Coordinator Treatment Action Group



Conflict of Interest Disclosure

I have no real or apparent conflicts of interest to report.



About Treatment Action Group

Treatment Action Group is an independent research and policy think tank focused on activism to accelerate research, treatment, access, and community information to prevent, treat, and cure HIV and its most common coinfections, hepatitis C virus (HCV) and tuberculosis (TB). www.treatmentactiongroup.org

TAG Treatment Action Group

#ADHERENCE2016 The fundamental concept of "HIV prevention" has changed radically in the past decade.

- First CDC PEP guidelines for non-occupational exposure in 2005
 Advent of PrEP
- •HPTN 052 and TasP
- The Gardner Cascade/Care and Treatment Continuum
- •Affordable Care Act

•Renewed urgency for SAPs and options for people who inject





A National TasP-Centric Prevention Response

•Calls for "test and treat" approaches in U.S.

High Impact Prevention

•Questions about the future of "prevention for negatives"





#ADHERENCE2016

NOTE: Categories may include funding across multiple agencies/programs; global category includes international HIV research at NIH. SOURCE: Kaiser Family Foundation, U.S. Federal Funding for HIV/AIDS: The President's FY 2016 Budget Request; February 2015.




#ADHERENCE2016

But there are substantive arguments against a singular TasP approach

•The notion that TasP alone can end an HIV epidemic, particularly among MSM, is controversial both within existing modeling and real world examples. *(Kretzschmar 2013; Powers 2014; Cohen 2012; Phillips 2014)*

Ethical Considerations



GRAPH: Powers, K et al. Impact of early-stage HIV transmission on treatment as prevention. Proceedings of the National Academy of Sciences. 2014.





We will have to maintain and expand options for those most vulnerable to HIV infection.

Equitable access to all the tools in our toolbox (PrEP, PEP, Clean Injection Supplies, STI screening)

Pursuing hopeful new tools in the pipeline (injectables, microbicides, other PrEPs, vaccines, and cures)

Maximize impact of the ACA

Medicaid expansion



Image courtesy of The Stigma Project



Complex questions will have to be answered for different **contexts and different populations**

- Not all interventions are created equal
- The effectiveness of the same innovation in different locations will change


Each key
 population has
 special
 considerations

Liu A, et al. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med. 2016

levels						
Characteristic	% PL*	AOR (95% CI)	P value			
Site San Francisco Miami DC	90 65 88	Ref 0.32 (0.17-0.60) 1.08 (0.54-2.19)	<0.001 0.82			
Race/Ethnicity White Latino Black Asian Other	91 77 57 84 82	Ref 0.81 (0.41-1.61) 0.28 (0.12-0.64) 0.72 (0.17-3.03) 0.42 (0.13-1.38)	0.55 <mark>0.003</mark> 0.65 0.15			
Living situation Rent or own housing Other	87 70	2.02 (1.14-3.55) Reference	0.02			
# condomless anal sex partners, past 3 mo 0-1 ≥2	75 89	Reference 1.82 (1.14-2.89)	0.01			

Independent predictors of protective DBS

*PL = Protective DBS levels (TFV-DP in DBS consistent with ≥4 doses/week)



Johnson, J. Toward Comprehensive HIV Prevention Service Delivery in the U.S. 2015. Available at: <u>www.treatmentactiongroup.org/hiv/publications</u>

Recommendations

#ADHERENCE2016

1. **Strengthen surveillance** to document HIV incidence, impact of prevention interventions and services, and progress toward reduced new infections and other health outcomes among all vulnerable populations.

2. Identify and support research priorities to **better define evidence-based prevention practices** and **implementation science**

3. Form a federal *Comprehensive HIV Prevention Service Delivery Initiative*, similar to the *HIV Care Continuum Initiative*, to identify and coordinate cross-agency responsibilities to address critical structural, social, and behavioral determinants of health and HIV risk reduction in key vulnerable populations.



4. Develop, disseminate, and support **best HIV prevention practices** to facilitate comprehensive, culturally competent, streamlined, ageappropriate, and rapid uptake among non-HIV care and other service providers

5. Develop **continua**, **process models**, **or similar heuristics** to guide comprehensive HIV prevention service delivery research and implementation

HIV Care Continuum



- Generally measurable, outcomes oriented
 - All pillars should apply to 100% of PLWHIV
- Captures collective attention
 - Highly visual, accessible, and reproducible
 - Works across stakeholder populations
 - Has galvanized advocacy, funding, and implementation of sound research, policies, and best practices

#ADHERENCE2016

Time for a Prevention Continuum?

- Enter care continuum
- Insurance and provider linkage a priority

#ADHERENCE2016

- Coordination of best practices and service delivery
- Strong framework for existing and emerging interventions/services

Time for a Prevention Continuum?


- Missed opportunities
 - Insurance navigation & enrollment
 - Risk assessments for HIV and other health disparities

#ADHERENCE2016

- Linkage to HIV-inclusive integrative/comprehensive care
- Coordination of structural, behavioral and biomedical interventions




Intervention-Based Cascade



Liu A, et al. 7th Int'l Conf on HIV Tx and Px Adherence (Abstract 80040). 2012 June 3-5.

Population-Based Cascade




#ADHERENCE2016

McNairy, El-Sadr, Clin Infect Dis. 2014;59:S12-15. Fauci, 2014.




The "HIV Neutral" Continuum of Care




New York City Department of Health and Mental Hygiene

#ADHERENCE2016 Infection cascade and prevention pathways model



Amico, KR. Developing an "HIV prevention cascade": Current approach and future directions. In: Program and abstracts of the 10th International Conference on HIV Treatment and Prevention Adherence (Miami). Washington, DC: International Association of Providers in


AIDS Care, 2015.




HIV-POSITIVE

HIV-NEGATIVE

Linkage to primary care	Screen for risk factors and barriers	Retention in care and services	Continued risk reduction, PrEP, PEP	Remain HIV-negative
HIV risk screenings, linkage case management for high-risk individuals, ACA navigation	Screen for STIs, mental health issues, drug use, domestic violence, trauma	Case management and linkage to housing and other ancillary services	+ Regular HIV testing and reevaluation of risk factors; adherence support	
	Assess attitudes, beliefs, behaviors, education, and	Mental health and drug-use counseling		
problem-solving skills	Peer support/navigation			
		Health literacy and education		
		Outreach and reengagement		








TAG/amfAR HIV Prevention Continuum

- Conceptual model
 - HIV testing is focal point
 - Identifies relevant:
 - Elements
 - Metrics



- Potential data sources for points along the process
- Links primary prevention with secondary prevention

Horn T, Sherwood J, Remien RH, Nash D, et al. Towards an Integrated Primary and Secondary HIV Prevention Continuum for the U.S.: A Cyclical Process Model. 2016. [submitted]



Let's start by being idealists

- What should prevention look like from start to finish for different individuals?
- How would we, in an ideal world, extrapolate this to populationlevel strategies?
- Then, how do we take those ideal plans and implement them in the real world?



THANK YOU!

JEREMIAH.JOHNSON@TREATMENTACTIONGROUP.ORG